Dr. Evans is a biopharmaceutical executive, translational scientist and entrepreneur with over twenty years experience in the research, development, and commercialization of pharmaceutical and natural product therapeutics for insulin resistance, type 2 diabetes, and obesity. Dr. Evans received his Ph.D. in Biochemistry from Drexel University (Philadelphia, PA), and received post-doctoral training in molecular biology, biochemistry, cell biology, and physiology at Dartmouth Medical School (Hanover, NH) and the University of Copenhagen (Copenhagen, Denmark). Dr. Evans’ previous corporate experience includes positions of increasing responsibility in diabetes drug discovery and development at Novartis (formerly Sandoz), Shaman, SUGEN, and Telik. Dr. Evans has also served as Vice President, Research & Development and Chief Scientific Officer of Medical Research Institute (San Francisco, CA), where he provided scientific leadership and expertise in product development, manufacturing, regulatory affairs, technology evaluation, and clinical research for a variety of highly successful dietary supplement products including NO2™, CE2™, and ALAmax™ (controlled release alpha-lipoic acid). Medical Research Institute was acquired by Natrol (Chatsworth, CA) in June, 2007. Dr. Evans has extensive expertise in the areas of insulin action, insulin resistance, natural product pharmacology, including antioxidants and nitric oxide biology, especially the regulation of nitric oxide production by natural compounds, including arginine and polyphenolic compounds. Dr. Evans has played a major role in the identification, development, and commercialization of a first-in-class controlled release alpha-lipoic acid for individuals with type 2 diabetes, and a first-in-class nitric oxide generator product for the sports nutrition industry.